top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.

Biblioteca

MARC Lista (tabellare)
Artificial Intelligence and Precision Oncology : Bridging Cancer Research and Clinical Decision Support / / edited by Zodwa Dlamini
Artificial Intelligence and Precision Oncology : Bridging Cancer Research and Clinical Decision Support / / edited by Zodwa Dlamini
Edizione [1st ed. 2023.]
Pubbl/distr/stampa Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023
Descrizione fisica 1 online resource (317 pages)
Disciplina 610.28563
Soggetto topico Cancer
Oncology
Medical screening
Cancer—Treatment
Tumor markers
Artificial Intelligence
Precision Medicine
Neoplasms - therapy
Epigenomics
Drug Design
Biomarkers, Tumor
Cancer Biology
Cancer Screening
Cancer Therapy
Tumour Biomarkers
ISBN 9783031215063
9783031215056
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Chapter 1. Introduction: The Application of AI in Precision Oncology: Tailoring Diagnosis, Treatment, and the Monitoring of Disease Progression to the Patient -- Part I. Artificial Intelligence for Screening, Diagnosis, Monitoring in Precision Oncology -- Chapter 2. Application of AI in Novel Biomarkers Detection that Induce Drug Resistance, Enhance Treatment Regimens and Advancing Precision Oncology -- Chapter 3. Use of Artificial Intelligence in Implementing Mainstream Precision Medicine to Improve Traditional Symptom-driven Practice of Medicine: Allowing Early Interventions and Tailoring better-personalized Cancer Treatments -- Chapter 4. AI as a Novel Approach for Exploring ccfNAs in Personalized Clinical Diagnosis and Prognosis: Providing Insight into the Decision-Making in Precision Oncology -- Chapter 5. AI-Enhanced Digital Pathology and Radiogenomics in Precision Oncology -- Part II. Artificial Intelligence and Omics in Precision Oncology -- Chapter 6. Epigenetics Analysis Using Artificial Intelligence in the Era of Precision Oncology -- Chapter 7. Association of Metabolomics with AI in Precision Oncology: Emerging Perspectives for More Effective Cancer Care -- Chapter 8. Artificial Intelligence Application to Microbiomics Data for Improved Clinical Decision Making in Precision Oncology -- Part III. Artificial Intelligence in Cancer Therapy and the Clinical Applications -- Chapter 9. AI and Nanotechnology in Realizing the Goal of Precision Medicine: Tailoring the Best Treatment for Personalized Cancer Treatment -- Chapter 10. Artificial Intelligence-Based Medical Devices Revolution in Cancer Screening: Impact into Clinical Practice -- Chapter 11. Intelligent Drug Design and Use for Cancer Treatment: The Roles of AI and Precision Oncology in Targeting Patient-Specific Splicing Profiles -- Chapter 12. Applying Artificial Intelligence Prediction Tools for Advancing Precision Oncology in Immunotherapy: Future Perspectives in Personalized Care -- Chapter 13. Employing AI-Powered Decision Support Systems in Recommending the Most Effective Therapeutic Approaches for Individual Cancer Patients: Maximizing Therapeutic Efficacy -- Chapter 14. AI-Pathway Companion in Clinical Decision Support: Enabling Personalized and Standardized Care Along Care Pathways in Oncology -- Chapter 15. AI Tools Offering Cancer Clinical Applications for Risk Predictor, Early Detection, Diagnosis, and Accurate Prognosis: Perspectives in Personalised Care -- Chapter 16. Conclusion and Insights into the Future of AI in Precision Oncology.
Record Nr. UNINA-9910739486103321
Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Biomarkers in cancer
Biomarkers in cancer
Pubbl/distr/stampa Auckland, New Zealand, : Libertas Academica, 2009-
Descrizione fisica 1 online resource
Disciplina 616.99405
Soggetto topico Tumor markers
Cancer
Biochemical markers
Oncology
Biological Markers
Biomarkers, Tumor
Neoplasms
Soggetto genere / forma Fulltext
Internet Resources.
Periodicals.
Soggetto non controllato Oncology
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Altri titoli varianti Journal of biomarkers in cancer
Record Nr. UNISA-996210175003316
Auckland, New Zealand, : Libertas Academica, 2009-
Materiale a stampa
Lo trovi qui: Univ. di Salerno
Opac: Controlla la disponibilità qui
Biomarkers in cancer
Biomarkers in cancer
Pubbl/distr/stampa Auckland, New Zealand, : Libertas Academica, 2009-
Descrizione fisica 1 online resource
Disciplina 616.99405
Soggetto topico Tumor markers
Cancer
Biochemical markers
Oncology
Biological Markers
Biomarkers, Tumor
Neoplasms
Soggetto genere / forma Fulltext
Internet Resources.
Periodicals.
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Altri titoli varianti Journal of biomarkers in cancer
Record Nr. UNINA-9910139256003321
Auckland, New Zealand, : Libertas Academica, 2009-
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Biomarkers in carcinoma of unknown primary / / Sulen Sarioglu, Ozgul Sagol, and Anil Aysal, editors
Biomarkers in carcinoma of unknown primary / / Sulen Sarioglu, Ozgul Sagol, and Anil Aysal, editors
Pubbl/distr/stampa Cham, Switzerland : , : Springer, , [2022]
Descrizione fisica 1 online resource (468 pages)
Disciplina 610.28
Soggetto topico Biochemical markers
Neoplasms, Unknown Primary
Biomarkers, Tumor
Carcinoma
ISBN 3-030-84432-3
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910523794403321
Cham, Switzerland : , : Springer, , [2022]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Biomarkers in medicine / / edited by Pinar Atukeren and Hafize Uzun
Biomarkers in medicine / / edited by Pinar Atukeren and Hafize Uzun
Autore Atukeren Pınar
Edizione [1st ed.]
Pubbl/distr/stampa Singapore : , : Bentham Science Publishers Pte. Ltd., , [2022]
Descrizione fisica 1 online resource (739 pages)
Disciplina 610.28
Soggetto topico Biomedical engineering
Radiology
Biomarkers
Biomarkers, Tumor
Soggetto non controllato Biochemical Markers
Clinical Biochemistry
Science
Medical
ISBN 981-5040-46-4
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- New Biomarkers and Immunotherapy Decision -- Abdurrahman Yigit1, Berkay Kuscu2, Ali Kirik2, Ruhsen Ozcaglayan2 and Cigdem Usul Afsar3,* -- NEW BIOMARKERS AND IMMUNOTHERAPY DECISION -- Principles of Cancer İmmunotherapy -- Tumor Immunology -- Therapeutic Approaches -- Immune Checkpoint Inhibitors (ICI) -- THE PREDICTIVE AND PROGNOSTIC MARKERS OF IMMUNOTHERAPY -- Immunotherapy Toxicity -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Gynecologic Tumors -- Selim Afsar1,* -- INTRODUCTION -- Ovarian and Fallopian Tube Cancers -- Carbohydrate Antigen 125 (CA125) -- Screening -- Prediction Models -- Prognosis -- Recurrence -- Human Epididymis Protein 4 (HE4) -- Diagnosis -- Prognosis -- Risk of Ovarian Malignancy Algorithm (ROMA) -- Circulating Cell-Free DNA (cfDNA) -- DNA Methylation -- Metabolites -- MicroRNAs -- Carcinoembryonic Antigen (CEA) -- Alpha-Fetoprotein (AFP) -- Inhibin B -- Human Chorionic Gonadotropin (hCG) -- Kallikreins -- Other Markers -- Uterine Cancer -- CA125 -- HE4 -- Genomic Classification -- Other Markers -- Cervical Cancer -- Squamous Cell Carcinoma Antigen (SCC-Ag) -- Other Markers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Urological Cancers -- Bulent Onal1,*, Mehmet Hamza Gultekin1, Muhammed Fatih Simsekoglu1, Berin Selcuk1 and Ahmet Gurbuz1 -- BIOMARKERS IN BLADDER CANCER -- Blood-based Biomarkers -- Tumor Cells -- CD8 Count and Immune Cells -- Matrix Metalloproteinase -- Epigenetic Markers -- Tissue-based Biomarkers -- Cell Cycle-based Markers -- Transmembrane- and Signaling-based Markers -- PDL/PDL1 -- mTOR -- MDR1 -- Human Epidermal Growth Factor Receptor 2 (HER2).
Apoptosis- and DNA Repair-Based Markers -- Multiplexed Markers -- Twenty-Gene Panel, GenomeDX Gene-Expression Assay -- Urine-based Biomarkers -- Fluorescence In situ Hybridization (FISH) -- Bladder Tumor Antigen (BTA) Tests -- Nuclear Matrix Protein-22 (NMP-22) Test -- ImmunoCyt Test -- CxBladder Test -- SUMMARY -- BIOMARKERS IN PROSTATE CANCER -- Blood-Based Biomarkers -- PSA or hK3 -- Free PSA (fPSA) -- Prostate Health Index (PHI) -- 4Kscore Test -- Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) -- Prostate-Specific Membrane Antigen (PSMA) -- Urine-Based Biomarkers -- PCA3 -- Gene Fusion -- SelectMDx -- Annexin A3 -- Tissue-Based Biomarkers -- α-Methylacyl Coenzyme A Racemase (AMACR) -- Epigenetic Modifications -- Genomic Expression Profiles -- Inherited Genetic Markers -- SUMMARY -- BIOMARKERS IN RENAL CELL CARCINOMA -- Diagnostic Biomarkers -- Carbonic Anhydrase IX (CAIX) -- Gene Expression Profile -- Urine Biomarkers -- Tissue Biomarkers -- Prognostic Biomarkers -- Routine Blood Biomarkers -- Von Hippel-Lindau (VHL) Gene -- VEGF -- Survivin -- p53 -- Ki-67 -- Phosphatase and Tensin Homolog (PTEN) -- Predictive Biomarkers -- Immune Checkpoint Inhibitors -- mTOR Inhibitors -- Pediatric Renal Tumors: -- SUMMARY -- BIOMARKERS IN TESTICULAR CANCER -- Alfa-fetoprotein (AFP) -- Human Chorionic Gonodotropin (HCG) -- Lactate Dehydrogenase (LDH) -- Potential Biomarkers in Future -- Placental Alkaline Phosphatase (PLAP) -- Oct-3/4, Sall 4, and CD 117 -- miRNAs -- SUMMARY -- NEXT GENERATION SEQUENCING -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Circulating Biomarkers in Thyroid Cancer -- Lebriz Uslu-Beşli1,* -- INTRODUCTION -- THYROID GLAND -- CLASSIFICATION OF THYROID CANCER -- MEDICAL MANAGEMENT OF THYROID CANCER -- Differentiated Thyroid Cancer -- Medullary Thyroid Cancer.
Anaplastic Thyroid Cancer -- SEROLOGICAL BIOMARKERS -- Thyroglobulin -- Anti-thyroglobulin Antibodies -- Calcitonin and Procalcitonin -- Carcinoembryonic Antigen -- Other Peptides -- LIQUID BIOPSY -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- DNA Methylation Biomarkers in Cancer: Current Clinical Utility and Future Perspectives -- Sinem Durmus1,*, Remise Gelisgen1 and Hafize Uzun2 -- INTRODUCTION -- DNA METHYLATION AND REGULATION MECHANISM -- DNA Methylation in Cancer -- Regional Hypermethylation -- Global Hypomethylation -- DNA Methylation Biomarkers in Cancer -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Circulating Biomarkers in Predicting Pathological Response to Neoadjuvant Therapy for Colorectal Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Tissue Based Biomarkers -- DNA Alterations: Polymorphisms -- Gene Expression -- MicroRNA (miRNA) -- Blood Based Biomarkers -- cfDNA and ctDNA -- cfmRNA and hTERT -- cfmiRNA -- CIRCULATING PROTEINS/PEPTIDES -- OTHER PREDICTIVE BIOMARKERS -- Thymidylate Synthase (TS) -- Epidermal Growth Factor Receptor (EGFR) -- Cyclooxygenase 2 (COX-2) -- Bax/bcl-2 -- P21 -- Ki-67 -- CEA -- ctDNA -- Circulating Tumour Cells (CTC) -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERANCES -- Circulating Biomarkers in the Management of Breast Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Carcinoembryonic Antigen (CEA) -- MUC-1 -- HER-2 -- Cytokeratins (CK) -- Specific Classes of Circulatory Biomarkers -- Proteins -- Autoantibodies -- Circulating Tumour Cells (CTC) -- Exosomes -- MicroRNA (miRNA) -- Circulating Cell-Free DNA (cfDNA).
BIOMARKERS FOR DIAGNOSIS AND PROGNOSIS OF BREAST CANCER -- MONITORING RESPONSE TO THERAPY AND SURVEILLANCE -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Clinical Application of Biomarkers for Hematologic Malignancies -- Nurgül Özgür Yurttaş1 and Ahmet Emre Eşkazan1,* -- INTRODUCTION -- BIOMARKERS IN MYELOID NEOPLASMS -- Acute Myeloid Leukemia -- CYTOGENETIC CLASSIFICATION OF AML -- MRD IN AML -- Myelodysplastic Syndrome -- CHROMOSOMAL ABNORMALITIES IN MDS -- Deletions of Chromosome 5 -- Monosomy 7 and Deletions of Chromosome 7 -- Diagnosis and Classification -- 5q-syndrome/MDS with an Isolated del(5q) -- Role of Cytogenetics in the Prognosis of MDS -- GENETIC MUTATIONS IN MDS -- Myeloproliferative Neoplasms -- Mutations in PV, ET, and PMF -- BIOMARKERS IN CHRONIC MYELOID LEUKEMIA -- Prognostic Factors at the Time of Diagnosis -- Use of the Mutational Analysis in CML -- Identification of Molecular Markers of Progression -- BIOMARKERS IN LYMPHOID NEOPLASMS -- BIOMARKERS IN ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA -- CYTOGENETIC AND MOLECULAR ABNORMALITIES IN ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA -- B-ALL/LBL with Recurrent Genetic Abnormalities -- T-ALL/LBL -- Cytogenetic Abnormalities in T-ALL/LBL -- Molecular Abnormalities in T-ALL/LBL -- EARLY T-CELL PRECURSOR ALL/LBL -- MRD IN ALL -- BIOMARKERS IN LYMPHOMAS -- Biomarkers of Genetic Changes -- B-Cell Lymphoma 6 (BCL6) -- Tumor Protein 53 (TP53) -- V-Myc Avian Myelocytomatosis Viral Oncogene Homolog (MYC) -- B-Cell Lymphoma 2 (BCL2) -- Myeloid Differentiation Primary Response 88 (MYD88) -- Other Genetic Biomarkers in B-Cell Lymphomas -- Other Genetic Biomarkers in Peripheral T-Cell Lymphoma (PTCL) -- Biomarkers Related to Epigenetic Changes -- Other Epigenetic Gene Features -- MicroRNA and LncRNA in Diagnosis and Prognosis of Lymphomas.
Other MicroRNAs and MicroRNA-Based Classifiers -- Immunophenotypic Biomarkers -- CD30 -- Bcl-6, Bcl-2, and Myc -- Cyclin D1 and SOX-11 -- TP53 and MDM2 -- Immunophenotypic Biomarkers -- Immunohistochemical Biomarkers of Peripheral T-Cell Lymphoma -- Microenvironment-related Biomarkers for Prognosis and Immunotherapy -- BIOMARKERS IN MULTIPLE MYELOMA -- STAGING SYSTEMS -- GENOMIC BIOMARKERS -- Gene Expression Profiling -- NOVEL BIOMARKERS -- Minimal Residual Disease -- Next-Generation Biomarkers in MM -- Immunotherapy-related Biomarkers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Applications of Biomarkers in Cancer Surgery -- Berrin Papila Kundaktepe1,* -- INTRODUCTION -- CIRCULATING TUMOR MARKERS: CLINICAL APPLICATIONS -- Applications Of Tumor Markers In Colorectal Cancer -- Applications of Tumor Markers in Hepatocellular Carcinoma (HCC) -- Applications of Tumor Markers in Pancreatic Adenocarcinoma -- Applications of Tumor Markers In Breast Cancer -- Circulating Tumor Cells -- ENDOCRINE TUMOR MARKERS -- Immunohistochemical and Circulating Tumor Markers of NETs -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- A Pathophysiological Approach To Current Biomarkers -- Aykut Oruc1,* and Gonul Simsek1 -- CARDIAC BIOMARKERS -- Cardiac Troponins -- Troponin Subunits -- Regulatory Function of Troponin -- Cardiac Troponins as a Biomarker for Acute Myocardial Infarction: The Pathophysiology -- Cardiac Troponins as a Biomarker in Congestive Heart Failure -- Heart-Type Fatty Acid Binding Protein -- Heart-Type Fatty Acid Binding Protein in Acute Myocardial Ischemia -- Glycogen Phosphorylase Isoenzyme BB -- Myocardial Oxygen Deficiency and GPBB Release: The Pathophysiology -- Glutathione S-Transferase P1 -- N-Terminal pro-Brain Natriuretic Peptide.
Pathophysiological Mechanisms in Synthesis and Secretion of BNP and NT-proBNP.
Record Nr. UNINA-9910795982603321
Atukeren Pınar  
Singapore : , : Bentham Science Publishers Pte. Ltd., , [2022]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Biomarkers in medicine / / edited by Pinar Atukeren and Hafize Uzun
Biomarkers in medicine / / edited by Pinar Atukeren and Hafize Uzun
Autore Atukeren Pınar
Edizione [1st ed.]
Pubbl/distr/stampa Singapore : , : Bentham Science Publishers Pte. Ltd., , [2022]
Descrizione fisica 1 online resource (739 pages)
Disciplina 610.28
Soggetto topico Biomedical engineering
Radiology
Biomarkers
Biomarkers, Tumor
Soggetto non controllato Biochemical Markers
Clinical Biochemistry
Science
Medical
ISBN 981-5040-46-4
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- New Biomarkers and Immunotherapy Decision -- Abdurrahman Yigit1, Berkay Kuscu2, Ali Kirik2, Ruhsen Ozcaglayan2 and Cigdem Usul Afsar3,* -- NEW BIOMARKERS AND IMMUNOTHERAPY DECISION -- Principles of Cancer İmmunotherapy -- Tumor Immunology -- Therapeutic Approaches -- Immune Checkpoint Inhibitors (ICI) -- THE PREDICTIVE AND PROGNOSTIC MARKERS OF IMMUNOTHERAPY -- Immunotherapy Toxicity -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Gynecologic Tumors -- Selim Afsar1,* -- INTRODUCTION -- Ovarian and Fallopian Tube Cancers -- Carbohydrate Antigen 125 (CA125) -- Screening -- Prediction Models -- Prognosis -- Recurrence -- Human Epididymis Protein 4 (HE4) -- Diagnosis -- Prognosis -- Risk of Ovarian Malignancy Algorithm (ROMA) -- Circulating Cell-Free DNA (cfDNA) -- DNA Methylation -- Metabolites -- MicroRNAs -- Carcinoembryonic Antigen (CEA) -- Alpha-Fetoprotein (AFP) -- Inhibin B -- Human Chorionic Gonadotropin (hCG) -- Kallikreins -- Other Markers -- Uterine Cancer -- CA125 -- HE4 -- Genomic Classification -- Other Markers -- Cervical Cancer -- Squamous Cell Carcinoma Antigen (SCC-Ag) -- Other Markers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Urological Cancers -- Bulent Onal1,*, Mehmet Hamza Gultekin1, Muhammed Fatih Simsekoglu1, Berin Selcuk1 and Ahmet Gurbuz1 -- BIOMARKERS IN BLADDER CANCER -- Blood-based Biomarkers -- Tumor Cells -- CD8 Count and Immune Cells -- Matrix Metalloproteinase -- Epigenetic Markers -- Tissue-based Biomarkers -- Cell Cycle-based Markers -- Transmembrane- and Signaling-based Markers -- PDL/PDL1 -- mTOR -- MDR1 -- Human Epidermal Growth Factor Receptor 2 (HER2).
Apoptosis- and DNA Repair-Based Markers -- Multiplexed Markers -- Twenty-Gene Panel, GenomeDX Gene-Expression Assay -- Urine-based Biomarkers -- Fluorescence In situ Hybridization (FISH) -- Bladder Tumor Antigen (BTA) Tests -- Nuclear Matrix Protein-22 (NMP-22) Test -- ImmunoCyt Test -- CxBladder Test -- SUMMARY -- BIOMARKERS IN PROSTATE CANCER -- Blood-Based Biomarkers -- PSA or hK3 -- Free PSA (fPSA) -- Prostate Health Index (PHI) -- 4Kscore Test -- Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) -- Prostate-Specific Membrane Antigen (PSMA) -- Urine-Based Biomarkers -- PCA3 -- Gene Fusion -- SelectMDx -- Annexin A3 -- Tissue-Based Biomarkers -- α-Methylacyl Coenzyme A Racemase (AMACR) -- Epigenetic Modifications -- Genomic Expression Profiles -- Inherited Genetic Markers -- SUMMARY -- BIOMARKERS IN RENAL CELL CARCINOMA -- Diagnostic Biomarkers -- Carbonic Anhydrase IX (CAIX) -- Gene Expression Profile -- Urine Biomarkers -- Tissue Biomarkers -- Prognostic Biomarkers -- Routine Blood Biomarkers -- Von Hippel-Lindau (VHL) Gene -- VEGF -- Survivin -- p53 -- Ki-67 -- Phosphatase and Tensin Homolog (PTEN) -- Predictive Biomarkers -- Immune Checkpoint Inhibitors -- mTOR Inhibitors -- Pediatric Renal Tumors: -- SUMMARY -- BIOMARKERS IN TESTICULAR CANCER -- Alfa-fetoprotein (AFP) -- Human Chorionic Gonodotropin (HCG) -- Lactate Dehydrogenase (LDH) -- Potential Biomarkers in Future -- Placental Alkaline Phosphatase (PLAP) -- Oct-3/4, Sall 4, and CD 117 -- miRNAs -- SUMMARY -- NEXT GENERATION SEQUENCING -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Circulating Biomarkers in Thyroid Cancer -- Lebriz Uslu-Beşli1,* -- INTRODUCTION -- THYROID GLAND -- CLASSIFICATION OF THYROID CANCER -- MEDICAL MANAGEMENT OF THYROID CANCER -- Differentiated Thyroid Cancer -- Medullary Thyroid Cancer.
Anaplastic Thyroid Cancer -- SEROLOGICAL BIOMARKERS -- Thyroglobulin -- Anti-thyroglobulin Antibodies -- Calcitonin and Procalcitonin -- Carcinoembryonic Antigen -- Other Peptides -- LIQUID BIOPSY -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- DNA Methylation Biomarkers in Cancer: Current Clinical Utility and Future Perspectives -- Sinem Durmus1,*, Remise Gelisgen1 and Hafize Uzun2 -- INTRODUCTION -- DNA METHYLATION AND REGULATION MECHANISM -- DNA Methylation in Cancer -- Regional Hypermethylation -- Global Hypomethylation -- DNA Methylation Biomarkers in Cancer -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Circulating Biomarkers in Predicting Pathological Response to Neoadjuvant Therapy for Colorectal Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Tissue Based Biomarkers -- DNA Alterations: Polymorphisms -- Gene Expression -- MicroRNA (miRNA) -- Blood Based Biomarkers -- cfDNA and ctDNA -- cfmRNA and hTERT -- cfmiRNA -- CIRCULATING PROTEINS/PEPTIDES -- OTHER PREDICTIVE BIOMARKERS -- Thymidylate Synthase (TS) -- Epidermal Growth Factor Receptor (EGFR) -- Cyclooxygenase 2 (COX-2) -- Bax/bcl-2 -- P21 -- Ki-67 -- CEA -- ctDNA -- Circulating Tumour Cells (CTC) -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERANCES -- Circulating Biomarkers in the Management of Breast Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Carcinoembryonic Antigen (CEA) -- MUC-1 -- HER-2 -- Cytokeratins (CK) -- Specific Classes of Circulatory Biomarkers -- Proteins -- Autoantibodies -- Circulating Tumour Cells (CTC) -- Exosomes -- MicroRNA (miRNA) -- Circulating Cell-Free DNA (cfDNA).
BIOMARKERS FOR DIAGNOSIS AND PROGNOSIS OF BREAST CANCER -- MONITORING RESPONSE TO THERAPY AND SURVEILLANCE -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Clinical Application of Biomarkers for Hematologic Malignancies -- Nurgül Özgür Yurttaş1 and Ahmet Emre Eşkazan1,* -- INTRODUCTION -- BIOMARKERS IN MYELOID NEOPLASMS -- Acute Myeloid Leukemia -- CYTOGENETIC CLASSIFICATION OF AML -- MRD IN AML -- Myelodysplastic Syndrome -- CHROMOSOMAL ABNORMALITIES IN MDS -- Deletions of Chromosome 5 -- Monosomy 7 and Deletions of Chromosome 7 -- Diagnosis and Classification -- 5q-syndrome/MDS with an Isolated del(5q) -- Role of Cytogenetics in the Prognosis of MDS -- GENETIC MUTATIONS IN MDS -- Myeloproliferative Neoplasms -- Mutations in PV, ET, and PMF -- BIOMARKERS IN CHRONIC MYELOID LEUKEMIA -- Prognostic Factors at the Time of Diagnosis -- Use of the Mutational Analysis in CML -- Identification of Molecular Markers of Progression -- BIOMARKERS IN LYMPHOID NEOPLASMS -- BIOMARKERS IN ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA -- CYTOGENETIC AND MOLECULAR ABNORMALITIES IN ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA -- B-ALL/LBL with Recurrent Genetic Abnormalities -- T-ALL/LBL -- Cytogenetic Abnormalities in T-ALL/LBL -- Molecular Abnormalities in T-ALL/LBL -- EARLY T-CELL PRECURSOR ALL/LBL -- MRD IN ALL -- BIOMARKERS IN LYMPHOMAS -- Biomarkers of Genetic Changes -- B-Cell Lymphoma 6 (BCL6) -- Tumor Protein 53 (TP53) -- V-Myc Avian Myelocytomatosis Viral Oncogene Homolog (MYC) -- B-Cell Lymphoma 2 (BCL2) -- Myeloid Differentiation Primary Response 88 (MYD88) -- Other Genetic Biomarkers in B-Cell Lymphomas -- Other Genetic Biomarkers in Peripheral T-Cell Lymphoma (PTCL) -- Biomarkers Related to Epigenetic Changes -- Other Epigenetic Gene Features -- MicroRNA and LncRNA in Diagnosis and Prognosis of Lymphomas.
Other MicroRNAs and MicroRNA-Based Classifiers -- Immunophenotypic Biomarkers -- CD30 -- Bcl-6, Bcl-2, and Myc -- Cyclin D1 and SOX-11 -- TP53 and MDM2 -- Immunophenotypic Biomarkers -- Immunohistochemical Biomarkers of Peripheral T-Cell Lymphoma -- Microenvironment-related Biomarkers for Prognosis and Immunotherapy -- BIOMARKERS IN MULTIPLE MYELOMA -- STAGING SYSTEMS -- GENOMIC BIOMARKERS -- Gene Expression Profiling -- NOVEL BIOMARKERS -- Minimal Residual Disease -- Next-Generation Biomarkers in MM -- Immunotherapy-related Biomarkers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Applications of Biomarkers in Cancer Surgery -- Berrin Papila Kundaktepe1,* -- INTRODUCTION -- CIRCULATING TUMOR MARKERS: CLINICAL APPLICATIONS -- Applications Of Tumor Markers In Colorectal Cancer -- Applications of Tumor Markers in Hepatocellular Carcinoma (HCC) -- Applications of Tumor Markers in Pancreatic Adenocarcinoma -- Applications of Tumor Markers In Breast Cancer -- Circulating Tumor Cells -- ENDOCRINE TUMOR MARKERS -- Immunohistochemical and Circulating Tumor Markers of NETs -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- A Pathophysiological Approach To Current Biomarkers -- Aykut Oruc1,* and Gonul Simsek1 -- CARDIAC BIOMARKERS -- Cardiac Troponins -- Troponin Subunits -- Regulatory Function of Troponin -- Cardiac Troponins as a Biomarker for Acute Myocardial Infarction: The Pathophysiology -- Cardiac Troponins as a Biomarker in Congestive Heart Failure -- Heart-Type Fatty Acid Binding Protein -- Heart-Type Fatty Acid Binding Protein in Acute Myocardial Ischemia -- Glycogen Phosphorylase Isoenzyme BB -- Myocardial Oxygen Deficiency and GPBB Release: The Pathophysiology -- Glutathione S-Transferase P1 -- N-Terminal pro-Brain Natriuretic Peptide.
Pathophysiological Mechanisms in Synthesis and Secretion of BNP and NT-proBNP.
Record Nr. UNINA-9910819897803321
Atukeren Pınar  
Singapore : , : Bentham Science Publishers Pte. Ltd., , [2022]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Cancer biomarkers : section A of Disease markers
Cancer biomarkers : section A of Disease markers
Pubbl/distr/stampa Amsterdam ; ; Washington, DC, : IOS Press
Disciplina 616.994075
Soggetto topico Cancer - Diagnosis
Neoplasms - diagnosis
Neoplasms - prevention & control
Neoplasms - therapy
Biomarkers, Tumor
Soggetto genere / forma Periodical
Periodicals.
ISSN 1875-8592
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Altri titoli varianti Section A of Disease markers
Record Nr. UNINA-9910154548603321
Amsterdam ; ; Washington, DC, : IOS Press
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Immunohistochemistry in Tumor Diagnostics [[electronic resource] /] / by Muin S.A. Tuffaha, Hans Guski, Glen Kristiansen
Immunohistochemistry in Tumor Diagnostics [[electronic resource] /] / by Muin S.A. Tuffaha, Hans Guski, Glen Kristiansen
Autore Tuffaha Muin S. A
Edizione [2nd ed. 2023.]
Pubbl/distr/stampa Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023
Descrizione fisica 1 online resource (373 pages)
Disciplina 616.07
Altri autori (Persone) GuskiHans
KristiansenGlen
Soggetto topico Pathology
Internal medicine
Immunohistochemistry
Neoplasms - diagnosis
Biomarkers, Tumor
Internal Medicine
ISBN 3-031-45024-8
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Introduction -- Chapter 1. Immunohistochemistry in tumor diagnosis -- Chapter 2. Immunohistochemical markers for the diagnosis of epithelial tumors -- Chapter 3. Markers and immunoprofile of pulmonary tumors and tumors of upper respiratory tract, middle and inner ear -- Chapter 4. Markers and immunoprofile of thymic epithelial tumors -- Chapter 5. Markers and immunoprofile of heart and pericardial tumors -- Chapter 6. Markers and immunoprofile of tumors of the oral cavity, oropharynx and salivary glands -- Chapter 7. Markers and immunoprofile of tumors of the gastrointestinal tract -- Chapter 8. Markers and immunoprofile of pancreatic tumors -- Chapter 9. Markers and immunoprofile of hepatobiliary tumors -- Chapter 10. Markers and immunoprofile of breast tumors -- Chapter 11. Markers and immunoprofile of tumors of female reproductive organs -- Chapter 12. Markers and immunoprofile of renal and urinary tract tumors -- Chapter 13. Markers and immunoprofile of male genital tract tumors -- Chapter 14. Markers and immunoprofile of tumors of endocrine organs and neuroendocrine tumors -- Chapter 15. Markers and immunoprofile of mesothelioma and tumors of the peritoneum -- Chapter 16. Markers and immunoprofile of lymphoid neoplasms -- Chapter 17. Markers and immunoprofile of myeloid neoplasms -- Chapter 18. Markers and immunoprofile of mastocytosis -- Chapter 19. Markers and immunoprofile of histiocytic and dendritic cell neoplasms -- Chapter 20. Markers and immunoprofile of stroma-derived neoplasms of lymphoid tissues -- Chapter 21. Markers and immunoprofile of skin tumors -- Chapter 22. Markers and immunoprofile of melanocytic tumors -- Chapter 23. Markers and immunoprofile of fibroblastic, myofibroblastic and fibrohistiocytic tumors -- Chapter 24. Markers and immunoprofile of muscle tumors -- Chapter 25. Markers and immunoprofile of vascular and pericytic (perivascular) tumors -- Chapter 26. Markers and immunoprofile of adipocytic tumors -- Chapter 27. Markers and immunoprofile of peripheral nerve- and nerve sheet tumors -- Chapter 28. Markers and immunoprofile of the central nervous system tumors -- Chapter 29. Markers and immunoprofile of Ewing sarcoma / primitive neuroectodermal tumors (PNET) and Ewing sarcoma-like tumors -- Chapter 30. Markers and immunoprofile of extraskeletal osseous and cartilaginous tumors -- Chapter 31. Markers and immunoprofile of miscellaneous tumors and tumors of uncertain differentiation -- Chapter 32. Immunohistochemistry and biomarkers for targeted tumor therapy -- Chapter 33. Markers to assist in the diagnosis of dysplasia and malignant transformation -- Chapter 34. Recommendations for the utility of immunohistochemical results in tumor diagnosis.
Record Nr. UNINA-9910805586103321
Tuffaha Muin S. A  
Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Mobile information systems
Mobile information systems
Pubbl/distr/stampa Amsterdam, : IOS Press
Descrizione fisica 1 online resource
Soggetto topico Mobile computing
Mobile communication systems
Mobile commerce
Computer networks
Tumor markers
Biomarkers, Tumor
Computer Communication Networks
Informatique mobile
Radiocommunications mobiles
Commerce mobile
Réseaux d'ordinateurs
Marqueurs tumoraux
Soggetto genere / forma Periodical
periodicals.
Periodicals.
Périodiques.
Soggetto non controllato Computer Science
ISSN 1875-905X
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Altri titoli varianti Journal of mobile information systems
Record Nr. UNISA-996321896103316
Amsterdam, : IOS Press
Materiale a stampa
Lo trovi qui: Univ. di Salerno
Opac: Controlla la disponibilità qui
Precision oncology and cancer biomarkers : issues at stake and matters of concern / / Anne Bremer, Roger Strand
Precision oncology and cancer biomarkers : issues at stake and matters of concern / / Anne Bremer, Roger Strand
Autore Bremer Anne
Pubbl/distr/stampa Cham, : Springer Nature, 2022
Descrizione fisica 1 online resource (288 p.)
Altri autori (Persone) StrandRoger
Collana Human Perspectives in Health Sciences and Technology
Soggetto topico Precision Medicine
Biomarkers, Tumor
Soggetto non controllato cancer biomarkers
Sociology of medicine
Science and Technology Studies
Oncology
Philosophy of medicine
precision oncology
personalised cancer treatments
health technology assessment
Open access
ISBN 3-030-92612-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910555236203321
Bremer Anne  
Cham, : Springer Nature, 2022
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui